source
- Eli Lilly cuts German weight-loss syringe investment by half amid new cost-cutting lawEli Lilly said it will cut its planned investment in Germany for the production of weight‑loss syringes. The company had originally earmarked $2.67 billion, but will now invest roughly half that a…
- Revolution Medicines eyes broader use of daraxonrasib pending FDA submissionRevolution Medicines' daraxonrasib has not yet been approved for metastatic pancreatic cancer after chemotherapy, but a recent ASCO plenary presentation generated strong interest. Analysts expect…